Evidence map›Paper›PMID 27605421›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2016

Absolute Measurement of Cardiac Injury-Induced microRNAs in Biofluids across Multiple Test Sites.

Karol L Thompson, Eric Boitier, Tao Chen, Philippe Couttet, Heidrun Ellinger-Ziegelbauer, Manuela Goetschy, Gregory Guillemain, Masayuki Kanki, Janet Kelsall, Claire Mariet and 12 more

Open access · greenAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron.Toxicological sciences : an official journal of the Society of Toxicology · 2021
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. microRNAs Make the Call in Cancer Personalized Medicine.Frontiers in cell and developmental biology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 7 countries.

Karol L ThompsonCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993.
Eric BoitierSanofi R&D, Disposition Safety and Animal Research, Vitry-Sur-Seine, France.
Tao ChenDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arizona 72079.
Philippe CouttetNovartis Pharma AG, Basel, CH 4057, Switzerland.
Heidrun Ellinger-ZiegelbauerToxicology, Bayer Pharma, Wuppertal, AG 42096, Germany.
Manuela GoetschyNovartis Pharma AG, Basel, CH 4057, Switzerland.
Gregory GuillemainNovartis Pharma AG, Basel, CH 4057, Switzerland.
Masayuki KankiAstellas Pharma Inc, Osaka 532-8514, Japan.
Janet KelsallAstraZeneca Ltd, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Claire MarietSanofi R&D, Disposition Safety and Animal Research, Vitry-Sur-Seine, France.
Catherine de La Moureyre-SpireInstitut De Recherches Servier, 78290 Croissy Sur Seine, France.
Peter MouritzenExiqon, Vedbaek DK-2950, Denmark.
Rounak NassirpourPfizer, Andover, Massachusetts 01810.
Raegan O'LoneILSI Health and Environmental Sciences Institute, Washington, DC 20005 Rolone@hesiglobal.org.
P Scott PineNational Institute of Standards and Technology, Stanford, California 94305.
Barry A RosenzweigCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993.
Tatiana SharapovaAbbVie, Abbott Park, Illinois 60064.
Aaron SmithEli Lilly, Indianapolis, Indiana 46285.
Hidefumi UchiyamaTakeda Pharmaceutical Co Ltd, Fujisawa, Kanagawa 251-8555, Japan.
Jian YanDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arizona 72079.
Peter S YuenNIH/NIDDK, Bethesda, Maryland 20892.
Russ WolfingerSAS Institute Inc, Cary, North Carolina 27513.
Novartis (Switzerland) · CHCenter for Drug Evaluation and Research · USNational Center for Toxicological Research · USSanofi (France) · FRAbbVie (United States) · USAstellas Pharma (Japan) · JPAstraZeneca (United Kingdom) · GBAVL (France) · FRBayer (Germany) · DEEli Lilly (United States) · USHealth and Environmental Sciences Institute · USHolbæk Sygehus · DKNational Institute of Standards and Technology · USNational Institutes of Health · USPfizer (United States) · USSAS Institute (United States) · USTakeda (Japan) · JP

Funding

Early Detection Of Renal InjuryZIADK043400 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI STAR, ROBERT A · 2009 to 2025
$9.5M
6 · The paper itself

Abstract

Extracellular microRNAs (miRNAs) represent a promising new source of toxicity biomarkers that are sensitive indicators of site of tissue injury. In order to establish reliable approaches for use in biomarker validation studies, the HESI technical committee on genomics initiated a multi-site study to assess sources of variance associated with quantitating levels of cardiac injury induced miRNAs in biofluids using RT-qPCR. Samples were generated at a central site using a model of acute cardiac injury induced in male Wistar rats by 0.5 mg/kg isoproterenol. Biofluid samples were sent to 11 sites for measurement of 3 cardiac enriched miRNAs (miR-1-3p, miR-208a-3p, and miR-499-5p) and 1 miRNA abundant in blood (miR-16-5p) or urine (miR-192-5p) by absolute quantification using calibration curves of synthetic miRNAs. The samples included serum and plasma prepared from blood collected at 4 h, urine collected from 6 to 24 h, and plasma prepared from blood collected at 24 h post subcutaneous injection. A 3 parameter logistic model was utilized to fit the calibration curve data and estimate levels of miRNAs in biofluid samples by inverse prediction. Most sites observed increased circulating levels of miR-1-3p and miR-208a-3p at 4 and 24 h after isoproterenol treatment, with no difference seen between serum and plasma. The biological differences in miRNA levels and sample type dominated as sources of variance, along with outlying performance by a few sites. The standard protocol established in this study was successfully implemented across multiple sites and provides a benchmark method for further improvements in quantitative assays for circulating miRNAs.

Indexed as

AnimalsBiomarkersHeart InjuriesIsoproterenolMaleMicroRNAsPlasmaRatsRats, WistarReal-Time Polymerase Chain ReactionSerumBiomarkersIsoproterenolMicroRNAsbiomarkerinterlaboratorymicroRNAvariance

Identifiers

PMID27605421
PMCPMC12129558
OpenAlexW2514766025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.